Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) Share Price Crosses Above 200 Day Moving Average – Here’s Why

Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) shares passed above its 200-day moving average during trading on Thursday. The stock has a 200-day moving average of $9.65 and traded as high as $10.0699. Shionogi & Co., Ltd. Unsponsored ADR shares last traded at $9.9699, with a volume of 73,749 shares changing hands.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on the stock. Zacks Research upgraded shares of Shionogi & Co., Ltd. Unsponsored ADR from a “hold” rating to a “strong-buy” rating in a research report on Thursday, October 15th. Jefferies Financial Group raised shares of Shionogi & Co., Ltd. Unsponsored ADR from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, July 14th. Three research analysts have rated the stock with a Strong Buy rating. According to data from MarketBeat, the company currently has a consensus rating of “Strong Buy”.

Shionogi & Co., Ltd. Unsponsored ADR Price Performance

The firm has a market cap of $16.97 billion, a P/E ratio of 11.08, a price-to-earnings-growth ratio of 3.41 and a beta of 0.10. The company has a current ratio of 1.14, a quick ratio of 1.00 and a debt-to-equity ratio of 0.01. The business has a 50-day moving average of $9.22 and a two-hundred day moving average of $9.65.

Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) last issued its earnings results on Thursday, October 29th. The company reported $0.08 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.13 by ($0.05). Shionogi & Co., Ltd. Unsponsored ADR had a return on equity of 14.32% and a net margin of 37.95%. The firm had revenue of $1.18 billion during the quarter, compared to analyst estimates of $1.11 billion. On average, sell-side analysts anticipate that Shionogi & Co., Ltd. Unsponsored ADR will post 0.83 earnings per share for the current fiscal year.

About Shionogi & Co., Ltd. Unsponsored ADR

Shionogi & Co, Ltd. is a Japanese pharmaceutical company headquartered in Osaka, Japan. Founded in 1878, the company researches, develops, manufactures and markets prescription medicines, with a longstanding focus on infectious diseases and specialty therapies.

Its products and development programs have included Xofluza (baloxavir marboxil), an oral treatment for influenza; Fetroja (cefiderocol), an antibiotic for certain difficult-to-treat Gram-negative bacterial infections; and medicines for central nervous system disorders, pain and other therapeutic areas.